Evommune | Chronic Inflammatory Disease | Scientific Posters
Publications & Posters
Research that inspires, data that informs, and knowledge that empowers.
We are proud to contribute to latest immunology and inflammation research through scientific publications and medical meetings.
June 2026
[Dual Inhibition of Meningeal Mast Cells and Trigeminal Neurons via MRGPRX2 Antagonism in Migraine](/content/wp-content/uploads/2026/06/Evommune_AHS_presentation_Role_of_MRGPRX2_in_Migraine.pdf "Dual Inhibition of Meningeal Mast Cells and Trigeminal Neurons via MRGPRX2 Antagonism in Migraine"/index.html)
Greg Dussor (presenting Author), Amanda Jacobson, Sreya Bagchi, Shiva Nematgorgani, Jane Brandon, Keerthana Nataranjan, Ishwarya Sankaranarayanan, Joseph Lesnak, Theodore Price, Lorena Riol-Blanco
American Headache Society (AHS) 2026
June 2026
[Targeting MRGPRX2 Addresses Unmet Need in Atopic Dermatitis: An In Silico Network Analysis](/content/wp-content/uploads/2026/06/Evommune_Cytoreason_Poster_FOCIS_2026.pdf "Targeting MRGPRX2 Addresses Unmet Need in Atopic Dermatitis: An In Silico Network Analysis"/index.html)
Amanda Jacobson, Sreya Bagchi, Jamie L. Harden, Victoria M. Shai, Mayan Briller, Moriah Gidoni, Alexandra Sirota-Madi and Lorena Riol-Blanco
Federation of Clinical Immunology Societies (FOCIS) 2026
June 2026
[Proteomic profiling of interstitial fluid from CIndU and CSU patients highlights the presence of shared MRGPRX2 ligands and inflammatory biomarkers](/content/wp-content/uploads/2026/06/Evommune_FOCIS_2026_Proteomic_Profiling_poster.pdf "Proteomic profiling of interstitial fluid from CIndU and CSU patients highlights the presence of shared MRGPRX2 ligands and inflammatory biomarkers"/index.html)
Sreya Bagchi, Han Gao, Jörg Scheffel, Nana Shi, Martin Metz, Lorena Riol-Blanco, Jamie L. Harden
Federation of Clinical Immunology Societies (FOCIS) 2026
May 2026
[EV301: a potent, novel IL18 inhibiting biologic demonstrating robust preclinical data for the treatment of atopic dermatitis](/content/wp-content/uploads/2026/05/Evommune_2026_SID_EVO301_poster.pdf "EV301: a potent, novel IL18 inhibiting biologic demonstrating robust preclinical data for the treatment of atopic dermatitis"/index.html)
Jamie L. Harden, Robert L. Whitener, Alexandra Pavel, Jaeger Patel, and Lorena Riol-Bianco
Presented at the Society of Investigative Dermatology (SID) (Chicago, IL), 2026
November 2025
[Targeting MRGPRX2: A Transformative Approach to Inflammatory Skin Conditions](/content/wp-content/uploads/2025/11/Evommune_2025_ISDS_EVO756_poster.pdf "Targeting MRGPRX2: A Transformative Approach to Inflammatory Skin Conditions"/index.html)
Sreya Bagchi et al.
Presented at the Inflammatory Skin Disease Summit 2025
November 2025
[EVO301: an IL18BP-SAFA biologic demonstrates prolonged residence in inflamed skin and efficacy in a preclinical atopic dermatitis model](/content/wp-content/uploads/2025/11/Evommune_2025_ISDS_EVO301_poster.pdf "EVO301: an IL18BP-SAFA biologic demonstrates prolonged residence in inflamed skin and efficacy in a preclinical atopic dermatitis model"/index.html)
Jamie Harden et al.
Presented at the Inflammatory Skin Disease Summit 2025
September 2025
WEBINAR: EADV Late-Breaker Presentation of EVO756 Phase 2 Data in Chronic Inducible Urticaria
Evommune Company Presentation
Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025
September 2025
[EVO756: An Oral MRGPRX2 Blocker Targeting Mast Cell-Neuron Signaling for Multiple Chronic Inflammatory Diseases](/content/wp-content/uploads/2025/09/2025_Cell-Neuro-Immune-Axis-Symposia-Poster.pdf "EVO756: An Oral MRGPRX2 Blocker Targeting Mast Cell-Neuron Signaling for Multiple Chronic Inflammatory Diseases"/index.html)
Amanda Jacobson, Sreya Bagchi, Alexandra Pavel, Claudia Montlollor-Abalate, Janice Drew, Polina Bukshpun, Kelsey Santisteban, Dan Burge, Jamie Harden, Jeegar Patel, Theodore J. Price , Lorena Riol-Blanco
Presented at the Cell Symposia: Neuro-immune axis: Charting the periphery meeting (New York City, NY), 2025
June 2025
[EVO756: A Promising Oral MRGPRX2 Inhibitor Showing Strong Preclinical and Phase 1 Results](/content/wp-content/uploads/2025/09/2025_FOCIS_Evommune.pdf "EVO756: A Promising Oral MRGPRX2 Inhibitor Showing Strong Preclinical and Phase 1 Results"/index.html)
Jamie Harden, Sreya Bagchi, Alexandra Pavel, Claudia Montlollor-Abalate, Andrea Kim, Janice Drew, Polina Bukshpun, Kelsey Santisteban, Dan Burge, Jeegar Patel, Lorena Riol-Blanco
Presented at the Federations of Clinical Immunological Societies (FOCIS) annual meeting (Boston, MA), 2025
May 2025
[EVO756: An Emerging Oral MRGPRX2 Blocker with Compelling Data from Early Studies](/content/wp-content/uploads/2025/09/2025_SID_Evommune.pdf "EVO756: An Emerging Oral MRGPRX2 Blocker with Compelling Data from Early Studies"/index.html)
Jamie Harden, Sreya Bagchi, Alexandra Pavel, Claudia Montlollor-Abalate, Andrea Kim, Janice Drew, Polina Bukshpun, Kelsey Santisteban, Dan Burge, Jeegar Patel, Lorena Riol-Blanco
Presented at the Society of Investigative Dermatology (SID) (San Diego, CA), 2025
May 2025
[EVO756 potently blocks MRGPRX2-mediated mast cell activation as well as MRGPRX2 and IgE-dependent synergistic responses](/content/wp-content/uploads/2025/09/042425_AAI_2025_Evommune.pdf "EVO756 potently blocks MRGPRX2-mediated mast cell activation as well as MRGPRX2 and IgE-dependent synergistic responses"/index.html)
Sreya Bagchi, Claudia M. Albalate, Alexandra Pavel, Jeegar Patel, Lorena R. Blanco, Jamie Harden
Presented at the Annual Meeting of American Association of Immunologist: IMMUNOLOGY2025 (Honolulu, Hawai'i)
December 2024
[EVO756, an oral MRGPRX2 antagonist, is well-tolerated and demonstrates target engagement: Results from a Phase 1 Study](/content/wp-content/uploads/2024/12/Evommune_GUF_2024_EVO756-HV001_Oral_Presentation_22Nov2024_2.pdf "EVO756, an oral MRGPRX2 antagonist, is well-tolerated and demonstrates target engagement: Results from a Phase 1 Study"/index.html)
Sarbjit S. Saini, MD, Kelly Devine, RN, BSN, CCRP, Tahira Mirza, MBBS, CCRP, Kristin L. Chichester, MS, Janice Drew, MPH, Polina Bukshpun, Kelsey Santisteban, Dan Burge, MD
Presented at the 7th GA²LEN Global Urticaria Forum (Berlin, Germany), 2024
December 2024
[EVO756 inhibits activation of MRGPRX2 in several in vitro models and correlates to human in vivo data](/content/wp-content/uploads/2024/12/Evommune_UCARE_Poster.pdf "EVO756 inhibits activation of MRGPRX2 in several in vitro models and correlates to human in vivo data"/index.html)
Sreya Bagchil, Jeegar Patel, Lorena Riol Blanco, Jamie L. Harden
Presented at the 7th GA²LEN Global Urticaria Forum (Berlin, Germany), 2024
May 2024
[Transcriptional profiling of primary human-skin derived mast cell activation by various MRGPRX2 agonists and inhibition with EVO756](/content/wp-content/uploads/2024/05/Evommune_AAI_2024_poster_final.pdf "Transcriptional profiling of primary human-skin derived mast cell activation by various MRGPRX2 agonists and inhibition with EVO756"/index.html)
Sreya Bagchi, Jeegar Patel, Lorena Riol Blanco, Jamie L. Harden
Presented at American Association of Immunology (AAI), 2024
November 2023
### [EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – a potential treatment for CSU and beyond](/content/wp-content/uploads/2023/12/EVO756_poster_PR.pdf "EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – a potential treatment for CSU and beyond
"/index.html)
Jamie L. Harden, Jelle Folkerts, See-Ying Tam, Stefan Frischbutter, Magda Babina4, Hans E. Hofland, Jeegar P. Patel, Marcus Maurer, and Stephen J. Galli
Presented at the Inflammatory Skin Disease Summit, 2023
November 2023
### [Role of MRGPRs in substance P signaling, itch, and mast cell activation](/content/wp-content/uploads/2023/12/Evommune_MRGPR_poster_WCI_2023.pdf "Role of MRGPRs in substance P signaling, itch, and mast cell activation
"/index.html)
Yanek Jiménez-Andrade, Lilah Gmyrek, Jamie Harden, Jeegar Patel, Hans Hofland, Jin Mo Park, and Ethan A. Lerner
Presented at the World Congress on Itch, 2023